Leone Rae Harr Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 313 6th Ave Se, Cut Bank, MT 59427 Phone: 406-873-2934 |
Nina Levitt Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 707 3rd St Se, Cut Bank, MT 59427 Phone: 406-873-5600 |
News Archive
The enzyme arginase-2 plays a major role in kidney failure, and blocking the action of this enzyme might lead to protection against renal disease in diabetes, according to researchers.
The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL), in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. The trial, led by Shaji Kumar, MD, of Mayo Clinic, is open for enrollment at Mayo Clinic (Rochester, Minn.), City of Hope Cancer Center (Duarte, Calif.) and the University of Chicago (Chicago, Ill).
FDA has approved a porcine insulin zinc suspension product as the first drug for treating diabetic dogs. Prior to the development of this product, the only treatment veterinarians could use on diabetic dogs was human insulin, which is less compatible with a dog's metabolic system.
Nephrologists must consider fluid overload effects when prescribing dialysis, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology. The fluid overload biomarker, N-terminal pro-brain-type natriuretic peptide, previously known as a "cardiac biomarker" in dialysis patients, is an important component of managing patients with kidney disease.
Researchers at the Institute for Autism Research at Canisius College have found a unique emotion recognition treatment highly effective for high-functioning children with autism spectrum disorder (HFASD).
› Verified 4 days ago